Autumn Glory Partners LLC Takes Position in Fresenius Medical Care AG (NYSE:FMS)

Autumn Glory Partners LLC bought a new stake in Fresenius Medical Care AG (NYSE:FMS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,198 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Allworth Financial LP increased its stake in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares during the period. MML Investors Services LLC increased its stake in Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after buying an additional 753 shares during the period. DAVENPORT & Co LLC increased its stake in Fresenius Medical Care by 1.5% in the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company’s stock worth $1,316,000 after buying an additional 862 shares during the period. Crossmark Global Holdings Inc. increased its stake in Fresenius Medical Care by 2.2% in the 4th quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock worth $1,456,000 after buying an additional 1,398 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in Fresenius Medical Care by 18.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock worth $211,000 after buying an additional 1,528 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on FMS shares. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial increased their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Finally, Berenberg Bank started coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price on the stock.

Fresenius Medical Care Stock Down 3.3 %

NYSE:FMS opened at $23.46 on Friday. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $25.25. The stock has a market capitalization of $13.76 billion, a P/E ratio of 19.38, a P/E/G ratio of 0.80 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company’s 50-day simple moving average is $23.47 and its 200-day simple moving average is $21.49.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.